Profile data is unavailable for this security.
About the company
Ginkgo Bioworks Holdings, Inc. operates as a horizontal platform for cell programming, providing end-to-end services for organizations across diverse markets, from food and agriculture to pharmaceuticals to industrial and specialty chemicals. Its segments include Cell Engineering and Biosecurity. The Cell Engineering consists of research and development services performed under collaboration and license agreements relating to its cell programming platform. Its cell programming platform includes two core assets: the Foundry, and Codebase. The Biosecurity segment consists of biomonitoring and bioinformatic testing products and services primarily provided to public health authorities. It also focuses on the design of next-generation cell therapies for autoimmune diseases. It uses its platform to develop and screen libraries of novel NK-specific and T-cell specific chimeric antigen receptor and switch receptor designs, which enable control and performance of immune cell-based therapies.
- Revenue in USD (TTM)184.34m
- Net income in USD-897.68m
- Incorporated2021
- Employees1.22k
- LocationGinkgo Bioworks Holdings Inc27 Drydock Avenue, 8Th FloorBOSTON 02210United StatesUSA
- Phone+1 (310) 209-7280
- Fax+1 (302) 655-5049
- Websitehttps://investors.ginkgobioworks.com/
More ▼
Mergers & acquisitions
| Acquired company | DNA:NYQ since announced | Transaction value |
|---|---|---|
| Proof Diagnostics Inc | 448.37% | -- |
| Patch Biosciences Inc | 535.61% | -- |
| Reverie Labs Inc | 535.61% | -- |
Data delayed at least 15 minutes, as of Nov 13 2024.
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Northwest Biotherapeutics Inc | 1.65m | -75.55m | 398.19m | 25.00 | -- | -- | -- | 242.06 | -0.0644 | -0.0644 | 0.0014 | -0.047 | 0.0581 | -- | -- | 65,800.00 | -260.06 | -381.58 | -- | -- | -- | -- | -4,479.03 | -6,479.25 | -- | -14.10 | -- | -- | 14.80 | 36.21 | 38.71 | -- | 77.88 | -- |
| C4 Therapeutics Inc | 33.67m | -105.50m | 415.06m | 145.00 | -- | 1.71 | -- | 12.33 | -1.70 | -1.70 | 0.5217 | 3.44 | 0.095 | -- | 6.21 | 232,193.10 | -29.76 | -25.91 | -33.20 | -29.45 | -- | -- | -313.35 | -292.35 | -- | -- | 0.00 | -- | -33.25 | 1.40 | -3.37 | -- | -8.68 | -- |
| Akebia Therapeutics Inc | 169.88m | -45.99m | 418.47m | 167.00 | -- | -- | -- | 2.46 | -0.2207 | -0.2207 | 0.8338 | -0.2383 | 0.7684 | 1.33 | 6.20 | 1,017,240.00 | -20.80 | -37.42 | -31.00 | -56.00 | 84.79 | 69.13 | -27.07 | -82.25 | 1.21 | -2.52 | -- | -- | -33.46 | -1.30 | 44.89 | -- | -- | -- |
| ProQR Therapeutics NV | 19.93m | -22.95m | 419.38m | 157.00 | -- | 9.53 | -- | 21.04 | -0.2822 | -0.2822 | 0.2449 | 0.4155 | 0.1406 | -- | -- | 126,939.30 | -15.98 | -35.51 | -20.63 | -40.51 | -- | -- | -113.62 | -926.31 | -- | -- | 0.3687 | -- | 118.51 | 10.58 | 56.35 | -- | 34.45 | -- |
| 4D Molecular Therapeutics Inc | 20.22m | -109.89m | 419.39m | 201.00 | -- | 0.7121 | -- | 20.74 | -2.22 | -2.22 | 0.435 | 11.33 | 0.0416 | -- | -- | 137,544.20 | -22.60 | -32.67 | -23.39 | -34.90 | -- | -- | -543.51 | -617.15 | -- | -- | 0.00 | -- | 562.29 | 7.96 | 6.19 | -- | 46.26 | -- |
| Lexicon Pharmaceuticals Inc | 3.64m | -202.11m | 459.10m | 285.00 | -- | 1.91 | -- | 126.09 | -0.7783 | -0.7783 | 0.0139 | 0.6639 | 0.0106 | 0.7239 | 2.20 | 12,775.44 | -58.57 | -24.41 | -63.55 | -29.01 | 92.47 | 98.49 | -5,550.87 | -84.92 | 11.49 | -11.96 | 0.2931 | -- | 766.19 | -54.71 | -73.74 | -- | 37.68 | -- |
| Ginkgo Bioworks Holdings Inc | 184.34m | -897.68m | 460.56m | 1.22k | -- | 5.42 | -- | 2.50 | -18.03 | -18.03 | 3.69 | 1.62 | 0.0941 | -- | 4.20 | 151,342.40 | -45.83 | -- | -50.04 | -- | 80.22 | -- | -486.98 | -- | -- | -- | 0.00 | -- | -47.36 | -- | 57.58 | -- | -- | -- |
| Organogenesis Holdings Inc | 448.39m | -16.54m | 464.01m | 862.00 | -- | 1.76 | -- | 1.03 | -0.125 | -0.125 | 3.38 | 1.99 | 1.00 | 4.27 | 4.49 | 520,176.30 | -3.70 | 5.46 | -4.51 | 6.90 | 75.14 | 74.94 | -3.69 | 4.81 | 2.42 | 8.33 | 0.2001 | 0.00 | -3.94 | 17.49 | -68.16 | -- | 67.34 | -- |
| GH Research PLC | -100.00bn | -100.00bn | 470.33m | 49.00 | -- | 2.37 | -- | -- | -- | -- | -- | 3.82 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 0.0038 | -- | -- | -- | -58.47 | -- | -- | -- |
| Cartesian Therapeutics Inc | 47.94m | -244.83m | 472.61m | 38.00 | -- | 628.56 | -- | 9.86 | -37.79 | -37.79 | 3.25 | 0.0315 | 0.1708 | -- | 9.86 | 1,261,526.00 | -87.23 | -43.66 | -94.16 | -66.84 | -- | -- | -510.72 | -136.35 | -- | -0.3505 | 0.00 | -- | -76.53 | 95.83 | -721.02 | -- | -25.27 | -- |
| Grail Inc | 109.74m | -2.88bn | 475.05m | 1.37k | -- | 0.1763 | -- | 4.33 | -99.94 | -99.94 | 3.91 | 86.80 | -- | -- | -- | 81,894.77 | -- | -47.45 | -- | -48.55 | 44.06 | -- | -2,627.35 | -5,118.86 | -- | -- | 0.00 | -- | 67.61 | -- | 72.85 | -- | -4.22 | -- |
| Absci Corp | 3.25m | -92.26m | 486.02m | 155.00 | -- | 2.19 | -- | 149.55 | -0.9331 | -0.9331 | 0.0327 | 1.95 | 0.0128 | -- | 2.03 | 20,967.74 | -36.20 | -- | -40.23 | -- | -- | -- | -2,838.89 | -- | -- | -129.46 | 0.0284 | -- | -0.5046 | -- | -5.40 | -- | -- | -- |
| Contineum Therapeutics Inc | 0.00 | -31.45m | 498.54m | 31.00 | -- | 2.29 | -- | -- | -1.24 | -1.24 | 0.00 | 8.46 | -- | -- | -- | 0.00 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 193.68 | -- | -- | -- |
| Foghorn Therapeutics Inc. | 25.52m | -91.22m | 515.90m | 116.00 | -- | -- | -- | 20.22 | -1.91 | -1.91 | 0.5133 | -0.5088 | 0.0821 | -- | -- | 219,956.90 | -29.34 | -31.35 | -35.57 | -35.69 | -- | -- | -357.53 | -777.33 | -- | -- | -- | -- | 77.63 | -- | 9.60 | -- | -4.50 | -- |
| Altimmune Inc | 409.00k | -101.35m | 522.37m | 59.00 | -- | 3.42 | -- | 1,277.19 | -1.62 | -1.62 | 0.0064 | 2.15 | 0.0023 | -- | 1.46 | 6,932.20 | -56.83 | -39.62 | -61.41 | -42.58 | -- | -- | -24,778.97 | -1,811.89 | -- | -- | 0.00 | -- | 726.47 | -47.15 | -4.41 | -- | -45.92 | -- |
Data as of Nov 13 2024. Currency figures normalised to Ginkgo Bioworks Holdings Inc's reporting currency: US Dollar USD
35.49%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Viking Global Investors LPas of 30 Jun 2024 | 3.58m | 8.30% |
| Baillie Gifford & Co.as of 30 Sep 2024 | 3.36m | 7.79% |
| The Vanguard Group, Inc.as of 30 Sep 2024 | 2.61m | 6.05% |
| Anchorage Capital Group LLCas of 30 Jun 2024 | 1.75m | 4.05% |
| BlackRock Fund Advisorsas of 30 Jun 2024 | 971.63k | 2.25% |
| Two Sigma Advisers LPas of 30 Jun 2024 | 786.09k | 1.82% |
| Legal & General Investment Management Ltd.as of 30 Jun 2024 | 671.70k | 1.56% |
| Glenview Capital Management LLCas of 30 Jun 2024 | 662.50k | 1.54% |
| Two Sigma Investments LPas of 30 Jun 2024 | 485.27k | 1.13% |
| D. E. Shaw & Co. LPas of 30 Jun 2024 | 433.91k | 1.01% |
More ▼
Data from 30 Jun 2024 - 30 Sep 2024Source: FactSet Research Systems Inc.
